Efficacy and Safety of a Selective URAT1 Inhibitor SHR4640 in Chinese Subjects with Hyperuricaemia: a Randomized Controlled Phase II Study

Yanwei Lin,Xiaoxiang Chen,Huihua Ding,Ping Ye,Jieruo Gu,Xiaoxia Wang,Zhenyu Jiang,Detian Li,Zhongming Wang,Wubin Long,Zhijun Li,Gengru Jiang,Xiaomei Li,Liqi Bi,Lindi Jiang,Jian Wu,Lian Guo,Xiaoyan Cai,Xin Lu,Qinkai Chen,Hong Chen,Ai Peng,Xiaoxia Zuo,Rui Ning,Zhe Zhang,Yanfei Tai,Tao Zhang,Chunde Bao

DOI: https://doi.org/10.1093/rheumatology/keab198

2021-01-01

Rheumatology

Abstract:Objective. To evaluate the efficacy and safety of SHR4640, a highly selective urate transporter 1 inhibitor, in Chinese subjects with hyperuricaemia. Methods. This was a randomized double-blind dose-ranging phase II study. Subjects whose serum uric acid (sUA) levels were >= 480 mu mol/l with gout, >= 480 mu mol/l without gout but with comorbidities, or >= 540 mu mol/l were enrolled. Subjects were randomly assigned (1:1:1:1:1) to receive once daily 2.5 mg, 5 mg, 10mg of SHR4640, 50mg of benzbromarone or placebo, respectively. The primary end point was the proportion of subjects who achieved target sUA level of <= 360 mu mol/l at week 5. Results. 99.5% of subjects (n = 197) were male and 95.9% of subjects had gout history. The proportions of subjects who achieved target sUA at week 5 were 32.5%, 72.5% and 61.5% in the 5 mg, 10 mg SHR4640 and benzbromarone groups, respectively, significantly higher than the placebo group (0%; P<0.05 for 5 mg and 10 mg SHR4640 group). The sUA was reduced by 32.7%, 46.8% and 41.8% at week 5 with 5 mg, 10 mg SHR4640 and benzbromarone, respectively, vs placebo (5.9%; P<0.001 for each comparison). The incidences of gout flares requiring intervention were similar among all groups. Occurrences of treatment-emergent adverse events (TEAEs) were comparable across all groups, and serious TEAEs were not reported. Conclusions. The present study indicated a superior sUA-lowering effect and well tolerated safety profile after 5-week treatment with once-daily 5 mg/10 mg of SHR4640 as compared with placebo in Chinese subjects with hyperuricaemia.